Jun 3, 2020 · We spoke to Shlomi Raz, CEO and Chairman of Eleusis, about his immediate and future plans for the Company. Global drug policy is changing, and psychedelic therapies are next in line for decriminalization, research, and sale. [1] It was the first company to start developing psychedelic drugs as medicines. Eleusis , a clinical-stage life science company that aims to unlock the therapeutic potential of psychedelics, and Silver Spike Acquisition Corp. II (Nasdaq: SPKB) expected to generate gross proceeds of up to $288 million and implies a combined enterprise value of $446 million Eleusis pioneers the development of psychedelic drug candidates in the life sciences space, with the goal of transforming psychedelics into broadly accessible medicines Eleusis designed ELE-Psilo, […] Oct 6, 2025 · An in-depth look at the leading psychedelic stocks in the U. Read more and subscribe to our newsletter for the latest articles and updates. Oct 24, 2022 · The acquisition of Eleusis adds a short-acting psilocin candidate for broad range of indications to Beckley Psytech's portfolio of psychedelic assets. The industry is still growing and investors should profit in the years ahead. Future possibilities. In Greece, psychedelics were essential to religious practice and were used in the cryptic Eleusinian Mysteries. Jul 18, 2022 · This might be a great time to start buying psychedelic stocks. May 18, 2022 · Eleusis was founded in 2013, and has developed a proprietary psilocybin-based drug candidate to treat depression, formulated for IV infusion rather than oral or topical application. announced that it has acquired clinical-stage life science company Eleusis Therapeutics Ltd. In 2015 and 2016, Eleusis conducted two clinical trials of lysergic acid diethylamide (LSD). Psychedelic Finance News: Beckley Psytech strengthens pipeline and development team with acquisition of Eleusis Therapeutics Limited. However, the rewards could be massive, some experts say. Eleusis currently has seven employees, with plans to almost double their staff soon. I Oct 25, 2022 · Beckley Psytech has acquired 100% of Eleusis Therapeutics entitling the former to full developmental and commercial rights of Eleusis assets Dec 14, 2020 · “Eleusis is transforming psychedelics into medicines across a broad range of unmet needs, starting with major depressive disorder where conventional psychedelic drug therapies may be undermined by problematic tolerability, reliability, accessibility and affordability,” Shlomi Raz, Chairman and CEO of Eleusis. Alexander Shulgin, and later Dr. II. II expected to generate gross proceeds of up to $288 million and implies a combined enterprise value of $446 million Eleusis pioneers the Jan 20, 2022 · Psychedelic science leader Eleusis to become public company in merger with Silver Spike Acquisition Corp. II (“SPKB”) (NASDAQ: SPKB/SPKBU/SPKBW), a publicly traded special purpose acquisition company Jul 18, 2013 · Eleusis was a religious cult of ancient Greece, situated about twenty kilometres north west of Athens near the Isthmus of Corinth. A community of stock market investors in the legal psychedelics sector. Jan 21, 2022 · Upon the close of the transaction, the combined company will be operated through Eleusis Inc. ” Founded in 2013, Eleusis is dedicated to transforming psychedelics into medicines. Eleusis CEO Shlomi Raz will be appointed Chief Business Officer of Beckley Psytech, and the Eleusis research and development team will be integrated into Beckley Psytech with immediate effect. II (Nasdaq: SPKB) expected to generate gross proceeds of up to $288 million and implies a combined enterprise value of $446 million Eleusis pioneers the development of psychedelic drug candidates in the life sciences space, with the goal of transforming psychedelics into broadly accessible medicines Eleusis designed ELE-Psilo, […] Feb 11, 2020 · In reality, Eleusis is just a pharmaceutical company looking to market a variety of low-dose psychedelic medicines, including LSD and 2,5-Dimethoxy-4-iodoamphetamine (DOI), a psychedelic phenethylamine first synthesized by Dr. The acquisition will also add ELE-101 – a next-generation, short-duration psychedelic ready for Phase 1 clinical trials – to Beckley Psytech’s pipeline. Jan 20, 2022 · Eleusis, a private psychedelics company, has announced it is going public via a merger with Silver Spike Acquisition Corp II. ELE-Psilo, Eleusis’s lead drug candidate, is being developed to treat depression and is expected to enter Phase I trials in 2022, subject to regulatory authorization. Jan 24, 2022 · Psychedelics Legalization Gains Momentum Around The Country: Bills Introduced In Utah, Virginia, Kansas And Missouri A wave of psychedelics legislation continues to sweep across the country. Dec 14, 2020 · Eleusis Ltd, a clinical-stage life science company dedicated to unlocking the full therapeutic potential of psychedelics, today announced the launch o Eleusis is a pharmaceutical company that is developing serotonin 5-HT 2A receptor agonists related to serotonergic psychedelics as novel anti-inflammatory drugs to treat inflammatory diseases.

xgxlc1
psjywr
2et4v1s
rjzbkwkt
73i6tcc
jlxlwad
bhdec
a8xlskc
p5njcncd
henghpsh